Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

As Moderna's Market Cap Nears $100-Billion, How Risky Is The Stock?

By Investing.com (Haris Anwar/Investing.com)Stock MarketsJul 15, 2021 07:28
uk.investing.com/analysis/as-modernas-market-cap-nears-100billion-how-risky-is-the-stock-200486613
As Moderna's Market Cap Nears $100-Billion, How Risky Is The Stock?
By Investing.com (Haris Anwar/Investing.com)   |  Jul 15, 2021 07:28
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

After its more than 450% surge during 2020, the meteoric rally in Moderna (NASDAQ:MRNA) shares continues this year. The gains—propelled by the biotech's breakthrough vaccine against COVID-19—have been so powerful that this 11-year-old company is now approaching a market capitalization of $100 billion.

The stock jumped almost 5% on Wednesday, to trade at a record $246.92, before closing at $246.40, valuing the Cambridge, Massachusetts-based Moderna at almost $99 billion.

Moderna Weekly Chart.
Moderna Weekly Chart.

This elevated level of valuation—which puts Moderna in the same league as global pharma giants such as Sanofi (NASDAQ:SNY) and GlaxoSmithKline (NYSE:GSK), also raises an important question: Where do MRNA shares go from here?

The answer to that question very much depends on the path the global health crisis takes and the company’s success at moving beyond vaccines in order to unlock the full potential of mRNA technology, on which the COVID vaccine is based, as a remedy for other diseases. For the time being, analyst predictions for the company's near-term sales potential range widely.

MRNA Consensus Estimates
MRNA Consensus Estimates

According to consensus estimates published on Investing.com, though the majority of analyts polled currently have a buy rating on the stock a significant minority don't hold the same conviction on the biotech.

Moderna, which had nominal sales before the pandemic, could bring in revenue ranging from $13 billion to $22 billion in 2021, according to analysts’ forecasts. But beyond this year, forecasting vaccine sales becomes trickier.

Morningstar analyst Karen Andersen in a Bloomberg report says the vaccine market could top out at $72 billion worldwide this year, and then fall to $65 billion in 2022 and $8 billion the following year.

“The extent of the slide will depend on how many people need booster shots, how often and whether Moderna, Pfizer (NYSE:PFE) and others will be able to raise prices to compensate for a smaller market,” the report says.

Already At Peak Valuation?

Analysts covering biotech companies, which thrive on their first set of products, say that in such cases, companies peak at about 10 times future sales, which they have the potential to fetch in the next three to five years.

Applying this rule to Moderna suggests that the company may have already achieved its peak valuation, and it will be tough for the stock to move higher from these levels. Companies as diverse as Alexion (NASDAQ:ALXN) and Gilead (NASDAQ:GILD) have shown investors a similar path after launching their breakthrough drugs.

Gilead, which launched a ground-breaking hepatitis C drug in late 2013, saw its sales surge to $19 billion in 2015 but then started to decline as competition grew. Gilead's value followed suit, dropping as much as $100 billion from its peak of almost $180 billion.

Long-Term Gilead Chart.
Long-Term Gilead Chart.

Beyond the COVID-19 pandemic, Moderna executives are optimistic their technology will bring cures for other respiratory-infectious diseases, such as respiratory syncytial virus, or RSV; and cytomegalovirus, or CMV; as well as other potential therapies for ailments including cancers and inflammatory diseases.

Betting on other breakthroughs may not bring windfalls as quickly as those fueled by the emergency authorization for the COVID vaccines. Most of Moderna’s experimental vaccines remain in early stage human trials, except its shot for cytomegalovirus. That could turn into a multi-billion-dollar product if it works. Moderna also plans human trials this year of a vaccine against Epstein-Barr virus, which causes mononucleosis.

Bottom Line

Moderna stock has proved a great bet for early investors. Its future path, however, is still uncertain after such a powerful rally which has pushed the stock beyond the fundamentals of future vaccine sales.

As Moderna's Market Cap Nears $100-Billion, How Risky Is The Stock?
 

Related Articles

As Moderna's Market Cap Nears $100-Billion, How Risky Is The Stock?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (5)
BV Karur
BV Karur Jul 20, 2021 12:50
Saved. See Saved Items.
This comment has already been saved in your Saved Items
but why Pfizer shares not increasing..infact Pfizer supply vaccines to all of Europe region
Abdul Samad
Abdul Samad Jul 16, 2021 9:21
Saved. See Saved Items.
This comment has already been saved in your Saved Items
should sell or hold Moderna
Madi Mainali
Madi Mainali Jul 15, 2021 17:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
awesome we love you
William Lam
William Lam Jul 15, 2021 9:58
Saved. See Saved Items.
This comment has already been saved in your Saved Items
To the moon
Foo Yeow
Foo Yeow Jul 15, 2021 9:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
U have to look at the revolutionary platform Moderna is creating vs a product it is currently selling now.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email